Related Experiment Video
Updated: Aug 16, 2026
Targeted Knockdown of Genes in the Choroid Plexus
Published on: June 16, 2023
Beta-MSH inhibits brain inflammation via MC(3)/(4) receptors and impaired NF-kappaB signaling
Ruta Muceniece1, Liga Zvejniece, Olga Kirjanova
1Faculty of Medicine, University of Latvia, Sarlotes St. 1a, Riga, LV-1001, Latvia. rutam@latnet.lv
Abstract:
The anti-inflammatory effects of melanocortin peptides have been demonstrated in different inflammation models. This is the first report describing the molecular mechanisms for the beta-MSH-induced suppression of bacterial lipopolisaccharide (LPS)-caused brain inflammation. We found that beta-MSH suppresses LPS-induced nuclear translocation of the transcription factor NF-kappaB, and inhibits the expression of inducible nitric oxide synthase, and the following nitric oxide overproduction in the brain, in vivo. Moreover, administering the preferentially MC(4) receptor selective antagonist HS014 blocked completely these effects, suggesting a tentative MC(4) receptor mediated mechanism of action for the beta-MSH. However, as HS014 shows quite low selectivity vis-à-vis the MC(3) receptor, a role for the MC(3) receptor cannot be excluded. In conclusion, our results show that beta-MSH is capable of inhibiting brain inflammation via activation of melanocortin receptors, of the subtypes 4 and/or 3.
Insights
Beta-melanocyte-stimulating hormone (beta-MSH) reduces brain inflammation caused by bacterial lipopolysaccharide (LPS). This effect is mediated by melanocortin receptors (MC3R/MC4R), inhibiting key inflammatory pathways.
Area of Science:
- Neuroimmunology
- Molecular Pharmacology
- Inflammation Research
Background:
- Melanocortin peptides are known for their anti-inflammatory properties.
- Brain inflammation, particularly that induced by bacterial lipopolysaccharide (LPS), is a significant pathological process.
- The precise molecular mechanisms underlying the anti-inflammatory actions of melanocortins in the brain remain incompletely understood.
Purpose of the Study:
- To elucidate the molecular mechanisms by which beta-melanocyte-stimulating hormone (beta-MSH) suppresses LPS-induced brain inflammation.
- To investigate the role of specific melanocortin receptor subtypes in mediating these anti-inflammatory effects.
Main Methods:
- In vivo studies utilizing a mouse model of LPS-induced brain inflammation.
- Assessment of nuclear translocation of the transcription factor NF-kappaB.
- Measurement of inducible nitric oxide synthase (iNOS) expression and nitric oxide (NO) production.
- Pharmacological blockade using a melanocortin receptor antagonist (HS014).
Main Results:
- Beta-MSH significantly suppressed LPS-induced nuclear translocation of NF-kappaB in the brain.
- Beta-MSH inhibited the expression of iNOS and subsequent nitric oxide overproduction.
- Administration of the MC4 receptor-selective antagonist HS014 completely blocked the anti-inflammatory effects of beta-MSH.
- The antagonist HS014's limited selectivity for MC3R suggests a potential role for MC3R as well.
Conclusions:
- Beta-melanocyte-stimulating hormone (beta-MSH) effectively inhibits LPS-induced brain inflammation.
- The anti-inflammatory effects are mediated through the activation of melanocortin receptors, likely subtypes MC4 and/or MC3.
- This study provides novel insights into the molecular pathways targeted by beta-MSH in neuroinflammation.
